248 related articles for article (PubMed ID: 30134648)
1. The Clinical Value of PELP1 for Breast Cancer: A Comparison with Multiple Cancers and Analysis in Breast Cancer Subtypes.
Wang X; Tsang JYS; Lee MA; Ni YB; Tong JH; Chan SK; Cheung SY; To KF; Tse GM
Cancer Res Treat; 2019 Apr; 51(2):706-717. PubMed ID: 30134648
[TBL] [Abstract][Full Text] [Related]
2. The prognostic significance of PELP1 expression in invasive breast cancer with emphasis on the ER-positive luminal-like subtype.
Habashy HO; Powe DG; Rakha EA; Ball G; Macmillan RD; Green AR; Ellis IO
Breast Cancer Res Treat; 2010 Apr; 120(3):603-12. PubMed ID: 19495959
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of proline, glutamic acid, leucine rich protein 1 (PELP1) in triple-negative breast cancer: a retrospective study on 129 cases.
Zhang Y; Dai J; McNamara KM; Bai B; Shi M; Chan MS; Liu M; Sasano H; Wang X; Li X; Liu L; Ma Y; Cao S; Xing Y; Zhao B; Song Y; Wang L
BMC Cancer; 2015 Oct; 15():699. PubMed ID: 26472563
[TBL] [Abstract][Full Text] [Related]
4. The prognostic value of estrogen receptor beta and proline-, glutamic acid- and leucine-rich protein 1 (PELP1) expression in ovarian cancer.
Aust S; Horak P; Pils D; Pils S; Grimm C; Horvat R; Tong D; Schmid B; Speiser P; Reinthaller A; Polterauer S
BMC Cancer; 2013 Mar; 13():115. PubMed ID: 23497172
[TBL] [Abstract][Full Text] [Related]
5. The pattern of proline, glutamic acid, and leucine-rich protein 1 expression in Chinese women with primary breast cancer.
Zhang Y; Wang P; Shi M; Sasano H; Chan MS; Dai J; Guo L; Liu M; Wang X; Ma Y; Wang L
Int J Biol Markers; 2014 Mar; 29(1):e1-7. PubMed ID: 24627205
[TBL] [Abstract][Full Text] [Related]
6. The Novel Marker GATA3 is Significantly More Sensitive Than Traditional Markers Mammaglobin and GCDFP15 for Identifying Breast Cancer in Surgical and Cytology Specimens of Metastatic and Matched Primary Tumors.
Sangoi AR; Shrestha B; Yang G; Mego O; Beck AH
Appl Immunohistochem Mol Morphol; 2016 Apr; 24(4):229-37. PubMed ID: 25906123
[TBL] [Abstract][Full Text] [Related]
7. Significantly increased PELP1 protein expression in primary and metastatic triple-negative breast carcinoma: comparison with GATA3 expression and PELP1's potential role in triple-negative breast carcinoma.
Dang DN; Raj G; Sarode V; Molberg KH; Vadlamudi RK; Peng Y
Hum Pathol; 2015 Dec; 46(12):1829-35. PubMed ID: 26428280
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of GATA3 expression in invasive breast cancer: differences in histological subtypes and immunohistochemically defined molecular subtypes.
Shaoxian T; Baohua Y; Xiaoli X; Yufan C; Xiaoyu T; Hongfen L; Rui B; Xiangjie S; Ruohong S; Wentao Y
J Clin Pathol; 2017 Nov; 70(11):926-934. PubMed ID: 28428285
[TBL] [Abstract][Full Text] [Related]
9. GATA-binding protein 3, gross cystic disease fluid protein-15 and mammaglobin have distinct prognostic implications in different invasive breast carcinoma subgroups.
Ni YB; Tsang JY; Chan SK; Tse GM
Histopathology; 2015 Jul; 67(1):96-105. PubMed ID: 25425335
[TBL] [Abstract][Full Text] [Related]
10. PELP1 is a novel oncogene in gastric tumorigenesis and negatively regulated by miR-15 family microRNAs.
Ma C; Miao C; Wang C; Song F; Luo M
Cancer Biomark; 2019; 26(1):1-9. PubMed ID: 31322541
[TBL] [Abstract][Full Text] [Related]
11. The social network of PELP1 and its implications in breast and prostate cancers.
Gonugunta VK; Miao L; Sareddy GR; Ravindranathan P; Vadlamudi R; Raj GV
Endocr Relat Cancer; 2014 Aug; 21(4):T79-86. PubMed ID: 24859989
[TBL] [Abstract][Full Text] [Related]
12. GATA3 expression in clinically useful groups of breast carcinoma: a comparison with GCDFP15 and mammaglobin for identifying paired primary and metastatic tumors.
Yang Y; Lu S; Zeng W; Xie S; Xiao S
Ann Diagn Pathol; 2017 Feb; 26():1-5. PubMed ID: 28038704
[TBL] [Abstract][Full Text] [Related]
13. Clinical Evaluation of Proline, Glutamic acid, and Leucine-Rich Protein 1 Expression in Astrocytomas and Correlations with the Proliferation Marker Ki-67.
Padmavathy KP; Vuttaradhi VK; Venu A; D'Cruze L; Saravanan R; Pitani R; Ganesh K; Pacharla H; Rayala SK; Prathiba D; Venkatraman G
J Mol Neurosci; 2021 Apr; 71(4):724-733. PubMed ID: 32964396
[TBL] [Abstract][Full Text] [Related]
14. PELP1 oncogenic functions involve alternative splicing via PRMT6.
Mann M; Zou Y; Chen Y; Brann D; Vadlamudi R
Mol Oncol; 2014 Mar; 8(2):389-400. PubMed ID: 24447537
[TBL] [Abstract][Full Text] [Related]
15. GATA-3 is superior to GCDFP-15 and mammaglobin to identify primary and metastatic breast cancer.
Ni YB; Tsang JYS; Shao MM; Chan SK; Cheung SY; Tong J; To KF; Tse GM
Breast Cancer Res Treat; 2018 May; 169(1):25-32. PubMed ID: 29340880
[TBL] [Abstract][Full Text] [Related]
16. Significance of PELP1/HDAC2/miR-200 regulatory network in EMT and metastasis of breast cancer.
Roy SS; Gonugunta VK; Bandyopadhyay A; Rao MK; Goodall GJ; Sun LZ; Tekmal RR; Vadlamudi RK
Oncogene; 2014 Jul; 33(28):3707-16. PubMed ID: 23975430
[TBL] [Abstract][Full Text] [Related]
17. PD-L1 expression and tumor infiltrating PD-1+Â lymphocytes associated with outcome in HER2+Â breast cancer patients.
Tsang JY; Au WL; Lo KY; Ni YB; Hlaing T; Hu J; Chan SK; Chan KF; Cheung SY; Tse GM
Breast Cancer Res Treat; 2017 Feb; 162(1):19-30. PubMed ID: 28058578
[TBL] [Abstract][Full Text] [Related]
18. Mammaglobin, GATA-binding protein 3 (GATA3), and epithelial growth factor receptor (EGFR) expression in different breast cancer subtypes and their clinical significance.
Kong X; Wang Q; Li J; Li M; Deng F; Li C
Eur J Histochem; 2022 Apr; 66(2):. PubMed ID: 35388661
[TBL] [Abstract][Full Text] [Related]
19. A First-in-Class Inhibitor of ER Coregulator PELP1 Targets ER+ Breast Cancer.
Altwegg KA; Viswanadhapalli S; Mann M; Chakravarty D; Krishnan S; Liu Z; Liu J; Pratap UP; Ebrahimi B; Sanchez JR; Li X; Ma S; Park BH; Santhamma B; Chen Y; Lai Z; Raj GV; Yuan Y; Zhou D; Sareddy GR; Tekmal RR; McHardy S; Huang TH; Rao MK; Vankayalapati H; Vadlamudi RK
Cancer Res; 2022 Oct; 82(20):3830-3844. PubMed ID: 35950923
[TBL] [Abstract][Full Text] [Related]
20. Overexpression of PELP1 in Lung Adenocarcinoma Promoted E
Zhang D; Dai J; Pan Y; Wang X; Qiao J; Sasano H; Zhao B; McNamara KM; Guan X; Liu L; Zhang Y; Chan MSM; Cao S; Liu M; Song S; Wang L
Pathol Oncol Res; 2021; 27():582443. PubMed ID: 34257530
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
